La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Exscientia Gestione

Gestione criteri di controllo 1/4

Exscientia's Il CEO è Dave Hallett, nominato in Feb2023, ha un mandato di 1.5 anni. possiede direttamente 0.001% delle azioni della società, per un valore di $ 7.98K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 3.6 anni.

Informazioni chiave

Dave Hallett

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.5yrs
Proprietà del CEO	0.001%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	3.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Feb 26

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Jan 11

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 12

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Aug 31

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Aug 25

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Jul 21

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Apr 22

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Dec 30

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Aug 31

Exscientia: Using AI To Power Drug Development

Aug 15

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

May 29

Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline

Apr 12

Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts

Jan 09

AMMINISTRATORE DELEGATO

Dave Hallett (55 yo)

1.5yrs

Mandato

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
David Hallett	Chief Scientific Officer	1.5yrs	Nessun dato	0.0012% £ 8.2k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.8yrs	UK£1.92m	0.038% £ 269.0k
John Overington	Chief Technology Officer	less than a year	Nessun dato	Nessun dato
Sara Sherman	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Dan Ireland	Executive VP of Legal & Company Secretary	1.6yrs	Nessun dato	Nessun dato
Parker Moss	Executive Vice President of Corporate Development	less than a year	Nessun dato	Nessun dato
Caroline Rowland	Chief People Officer	1.9yrs	Nessun dato	Nessun dato
Richard Law	Chief Business Officer	no data	Nessun dato	Nessun dato
Nikolaus Krall	Executive Vice President of Precision Medicine	1.6yrs	Nessun dato	Nessun dato
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	Nessun dato	Nessun dato

1.5yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di EXAI non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Hallett	Chief Scientific Officer	less than a year	Nessun dato	0.0012% £ 8.2k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	3.8yrs	UK£1.92m	0.038% £ 269.0k
Elizabeth Crain	Independent Non-Executive Chairman	3.5yrs	UK£282.03k	0.055% £ 387.0k
Mario Polywka	Independent Non-Executive Director	6.9yrs	UK£201.69k	0.045% £ 317.1k
Robert Ghenchev	Independent Non-Executive Director	4.3yrs	Nessun dato	Nessun dato
Franziska Michor	Independent Director	1.3yrs	UK£178.86k	0.0051% £ 36.3k

3.6yrs

Durata media

51yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EXAI sono considerati esperti (durata media dell'incarico 3.6 anni).

Exscientia Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Scientific Officer notifies of intention to sell stock

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Chief Scientific Officer notifies of intention to sell stock

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 60%

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

Chief Scientific Officer notifies of intention to sell stock

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia: Too Much Pessimism

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia: Drug Discovery Platform Attracting Partners And Cash

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

Consensus EPS estimates fall by 22%

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 12%, EPS upgraded

New minor risk - Shareholder dilution

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Consensus revenue estimates increase by 23%

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates increase by 18%

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Consensus EPS estimates upgraded to UK£1.49 loss, revenue downgraded

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 29%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Consensus forecasts updated

Third quarter 2022 earnings released

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Consensus forecasts updated

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia: Using AI To Power Drug Development

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Consensus forecasts updated